MAIA Biotechnology Business Summary

MAIA Biotechnology, Inc. (MAIA) is a clinical-stage biopharmaceutical company that operates on a high-risk, high-reward R&D model focused on the development and eventual commercialization or licensing of first-in-class immuno-oncology therapies. The company currently generates no product revenue, instead funding its operations through private placements, grants—such as a $2.3 million NIH award—and strategic collaborations, including a clinical supply agreement with Roche. MAIA’s primary business segment is centered on its proprietary telomere-targeting platform, led by its candidate THIO (ateganosine), which is currently in Phase 3 pivotal trials for advanced non-small cell lung cancer (NSCLC). In the competitive landscape, MAIA contends with oncology-focused firms like Jazz Pharmaceuticals, Karyopharm Therapeutics, and C4 Therapeutics; however, it distinguishes itself as the only developer with a direct telomere-targeting agent in clinical trials, positioning it as a niche leader in the "telomerase-positive" cancer treatment market. MAIA was co-founded and is led by Chairman and CEO Dr. Vlad Vitoc, an M.D. and M.B.A. with over 20 years of experience in medical affairs and commercial strategy for over 25 tumor types. The scientific foundation of the company is anchored by Chief Scientific Officer Dr. Sergei M. Gryaznov, the co-inventor of the telomere-targeting approach and a renowned expert in nucleoside chemistry, alongside Chief Medical Officer Dr. Mihail Obrocea, who previously held senior roles at Atara Biotherapeutics and AbbVie. The leadership team is supported by a board of directors that includes Lead Independent Director Stan V. Smith and TransUnion executive Steven M. Chaouki. Notable institutional backing comes from major asset managers such as Vanguard Group, BlackRock, and State Street, while significant insider ownership—exceeding 13% as of early 2026—reflects strong internal conviction in the company’s clinical milestones.